ReNeuron cleared to proceed with groundbreaking stem cell study

An independent monitoring board has given ReNeuron a green light to continue with a pioneering study in which stem cells are being injected into the brains of stroke victims. After reviewing the responses of the first three patients, the biotech will now try a higher dose. "Data from the laboratory safety tests, neurological examinations and neurofunctional tests conducted thus far indicate that the ReN001 treatment is safe and well-tolerated at the initial dose," said the U.K. company. Story

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.